Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Moderna stock is undervalued with a $97 price target, strong COVID-19 revenue, promising pipeline, and long-term growth. Read ...

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

It was later granted full FDA approval in August 2021 for people ages 16 and older. Pfizer’s and Moderna's vaccine has been updated over time to target currently circulating variants ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Unrestricted access to all Essential and Insights content Access to the PRWeek Consultancy Tracker and the Top 150 Monthly Trading Tracker Hub In-depth reports including quarterly and annual ...

Marty Makary, an outspoken critic of the nation’s food and drug regulator, stands to shake up the FDA’s standards in science ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...

said the Drug Control Authority (DCA) agreed to give conditional approval to Spikevax, or what is commonly known as the Moderna Covid-19 vaccine.